Pesquisar
Zai Lab Ltd
ZLABAdicionar à lista de desejos
20.590USD
+0.260+1.28%
Fechamento 05/15, 16:00（ET）Cotações atrasadas em 15 min
2.33BValor de mercado
PerdaP/L TTM
Mais detalhes de Zai Lab Ltd Empresa
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Informações de Zai Lab Ltd
Código da empresaZLAB
Nome da EmpresaZai Lab Ltd
Data de listagemSep 28, 2020
CEODu (Ying)
Número de funcionários1869
Tipo de títulosDepository Receipt
Fim do ano fiscalSep 28
EndereçoBuilding B, 899 Halei Road, Pudong
CidadeSHANGHAI
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísChina
Código postal201203
Telefone862161632588
Sitehttps://www.zailaboratory.com/
Código da empresaZLAB
Data de listagemSep 28, 2020
CEODu (Ying)
Executivos da empresa Zai Lab Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
117.60K
+22.60%
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+10.86%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-8.50%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
19.15K
-4.46%
Dr. Ying (Samantha) Du, Ph.D.
Dr. Ying (Samantha) Du, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Mr. Peter Karl Wirth, J.D.
Mr. Peter Karl Wirth, J.D.
Independent Director
Independent Director
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Frazor Titus Edmondson, J.D.
Mr. Frazor Titus Edmondson, J.D.
Company Secretary, Chief Legal Officer
Company Secretary, Chief Legal Officer
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
117.60K
+22.60%
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+10.86%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-8.50%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
19.15K
-4.46%
Dr. Ying (Samantha) Du, Ph.D.
Dr. Ying (Samantha) Du, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
Por EmpresaUSD
Nome
Receita
Proporção
ZEJULA
189.04M
41.35%
VYVGART
94.20M
20.60%
NUZYRA
60.84M
13.31%
Optune
48.33M
10.57%
QINLOCK
35.61M
7.79%
Outro
29.17M
6.38%
Por RegiãoUSD
Nome
Receita
Proporção
China (Mainland)
460.16M
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
ZEJULA
189.04M
41.35%
VYVGART
94.20M
20.60%
NUZYRA
60.84M
13.31%
Optune
48.33M
10.57%
QINLOCK
35.61M
7.79%
Outro
29.17M
6.38%
Distribuição de ações
Atualizado em: qui, 14 de mai
Atualizado em: qui, 14 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
RTW Investments L.P.
6.19%
RA Capital Management, LP
5.11%
Norges Bank Investment Management (NBIM)
3.42%
Frazier Life Sciences Management, L.P.
1.69%
ClearBridge Investments, LLC
1.61%
Outro
81.97%
Investidores
Investidores
Proporção
RTW Investments L.P.
6.19%
RA Capital Management, LP
5.11%
Norges Bank Investment Management (NBIM)
3.42%
Frazier Life Sciences Management, L.P.
1.69%
ClearBridge Investments, LLC
1.61%
Outro
81.97%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
11.71%
Investment Advisor
5.60%
Venture Capital
5.36%
Hedge Fund
4.22%
Sovereign Wealth Fund
3.42%
Individual Investor
1.91%
Private Equity
1.69%
Research Firm
1.50%
Pension Fund
0.05%
Outro
64.54%
Participação acionária institucional
Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q4
280
37.42M
42.38%
--
2026Q1
352
37.82M
33.67%
-10.78M
2025Q4
370
44.73M
39.84%
-12.84M
2025Q3
372
46.61M
41.70%
-15.37M
2025Q2
394
60.58M
54.15%
-11.96M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
RTW Investments L.P.
6.96M
6.14%
+4.67M
+203.71%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
3.84M
3.39%
+3.84M
--
Dec 31, 2025
Frazier Life Sciences Management, L.P.
1.90M
1.68%
+275.00K
+16.90%
Dec 31, 2025
ClearBridge Investments, LLC
1.81M
1.59%
-1.71M
-48.63%
Dec 31, 2025
Citadel Advisors LLC
1.69M
1.49%
+700.80K
+71.00%
Dec 31, 2025
Fidelity Management & Research Company LLC
1.44M
1.27%
-2.84M
-66.32%
Dec 31, 2025
Baron Capital Management, Inc.
1.42M
1.25%
+46.76K
+3.41%
Dec 31, 2025
Adar1 Capital Management LLC
1.25M
1.1%
+377.74K
+43.48%
Dec 31, 2025
Du (Ying Samantha)
1.06M
0.94%
+145.74K
+15.88%
Mar 11, 2026
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Tema Oncology ETF
1.67%
ALPS Medical Breakthroughs ETF
1.19%
Virtus LifeSci Biotech Products ETF
0.97%
Invesco Golden Dragon China ETF
0.58%
National Security Emerging Markets Index ETF
0.39%
iShares Biotechnology ETF
0.18%
Capital Group New Geography Equity ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.03%
Ver Mais
Tema Oncology ETF
Proporção1.67%
ALPS Medical Breakthroughs ETF
Proporção1.19%
Virtus LifeSci Biotech Products ETF
Proporção0.97%
Invesco Golden Dragon China ETF
Proporção0.58%
National Security Emerging Markets Index ETF
Proporção0.39%
iShares Biotechnology ETF
Proporção0.18%
Capital Group New Geography Equity ETF
Proporção0.15%
ProShares Ultra Nasdaq Biotechnology
Proporção0.12%
Invesco Nasdaq Biotechnology ETF
Proporção0.12%
ActivePassive International Equity ETF
Proporção0.03%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
